A detailed history of China Universal Asset Management Co., Ltd. transactions in Ab Cellera Biologics Inc. stock. As of the latest transaction made, China Universal Asset Management Co., Ltd. holds 56,674 shares of ABCL stock, worth $165,488. This represents 0.02% of its overall portfolio holdings.

Number of Shares
56,674
Previous 34,546 64.05%
Holding current value
$165,488
Previous $102,000 43.14%
% of portfolio
0.02%
Previous 0.01%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 25, 2024

BUY
$2.39 - $3.49 $52,885 - $77,226
22,128 Added 64.05%
56,674 $146,000
Q2 2024

Jul 19, 2024

SELL
$2.73 - $4.73 $59,404 - $102,924
-21,760 Reduced 38.65%
34,546 $102,000
Q1 2024

Apr 29, 2024

BUY
$4.29 - $5.97 $97,554 - $135,757
22,740 Added 67.75%
56,306 $255,000
Q4 2023

May 21, 2024

SELL
$3.91 - $5.93 $88,913 - $134,848
-22,740 Reduced 40.39%
33,566 $191,000
Q4 2023

Jan 23, 2024

BUY
$3.91 - $5.93 $102,219 - $155,027
26,143 Added 352.19%
33,566 $192,000
Q3 2023

May 21, 2024

BUY
$4.6 - $7.95 $16,734 - $28,922
3,638 Added 96.12%
7,423 $34,000
Q3 2023

Oct 30, 2023

BUY
$4.6 - $7.95 $16,734 - $28,922
3,638 Added 96.12%
7,423 $34,000
Q2 2023

May 21, 2024

SELL
$5.66 - $7.59 $639 - $857
-113 Reduced 2.9%
3,785 $24,000
Q2 2023

Jul 27, 2023

SELL
$5.66 - $7.59 $639 - $857
-113 Reduced 2.9%
3,785 $24,000
Q1 2023

May 21, 2024

BUY
$7.31 - $11.18 $7,251 - $11,090
992 Added 34.14%
3,898 $29,000
Q1 2023

Apr 27, 2023

BUY
$7.31 - $11.18 $7,251 - $11,090
992 Added 34.14%
3,898 $29,000
Q4 2022

May 21, 2024

SELL
$9.48 - $14.52 $506,232 - $775,368
-53,400 Reduced 94.84%
2,906 $29,000
Q4 2022

Jan 31, 2023

BUY
$9.48 - $14.52 $2,237 - $3,426
236 Added 8.84%
2,906 $29,000
Q3 2022

Oct 21, 2022

BUY
$9.2 - $13.68 $24,563 - $36,525
2,670 New
2,670 $26,000

Others Institutions Holding ABCL

About AbCellera Biologics Inc.


  • Ticker ABCL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 285,139,008
  • Market Cap $833M
  • Description
  • AbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, artificial intelligence-powered antibody discovery platform searches and analyzes the database of natural immune systems to find antibodies that could be developed as drugs. As of December 31, 2021, the company had 156 discovery programs that are either completed, in ...
More about ABCL
Track This Portfolio

Track China Universal Asset Management Co., Ltd. Portfolio

Follow China Universal Asset Management Co., Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of China Universal Asset Management Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on China Universal Asset Management Co., Ltd. with notifications on news.